Long-Term Survival in HIV Positive Patients with up to 15 Years of Antiretroviral Therapy
Authors:
- Hamish McManusHMHamish McManus
- Mark BoydMBMark Boyd
- Jennifer BroomJBJennifer Broom
- Australian Hiv Observational DatabaseADAustralian Hiv Observational Database
Open Access
- 7 November 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (11) , e48839
Abstract
Life expectancy has increased for newly diagnosed HIV patients since the inception of combination antiretroviral treatment (cART), but there remains a need to better understand the characteristics of long-term survival in HIV-positive patients. We examined long-term survival in HIV-positive patients receiving cART in the Australian HIV Observational Database (AHOD), to describe changes in mortality compared to the general population and to develop longer-term survival models. Data were examined from 2,675 HIV-positive participants in AHOD who started cART. Standardised mortality ratios (SMR) were calculated by age, sex and calendar year across prognostic characteristics using Australian Bureau of Statistics national data as reference. SMRs were examined by years of duration of cART by CD4 and similarly by viral load. Survival was analysed using Cox-proportional hazards and parametric survival models. The overall SMR for all-cause mortality was 3.5 (95% CI: 3.0–4.0). SMRs by CD4 count were 8.6 (95% CI: 7.2–10.2) for CD4<350 cells/µl; 2.1 (95% CI: 1.5–2.9) for CD4 = 350–499 cells/µl; and 1.5 (95% CI: 1.1–2.0) for CD4≥500 cells/µl. SMRs for patients with CD4 counts <350 cells/µL were much higher than for patients with higher CD4 counts across all durations of cART. SMRs for patients with viral loads greater than 400 copies/ml were much higher across all durations of cART. Multivariate models demonstrated improved survival associated with increased recent CD4, reduced recent viral load, younger patients, absence of HBVsAg-positive ever, year of HIV diagnosis and incidence of ADI. Parametric models showed a fairly constant mortality risk by year of cART up to 15 years of treatment. Observed mortality remained fairly constant by duration of cART and was modelled accurately by accepted prognostic factors. These rates did not vary much by duration of treatment. Changes in mortality with age were similar to those in the Australian general population.Keywords
This publication has 24 references indexed in Scilit:
- Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) studyHIV Medicine, 2011
- Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study*HIV Medicine, 2011
- Estimating the impact of antiretroviral therapy: regional and global estimates of life-years gained among adultsSexually Transmitted Infections, 2010
- Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individualsAIDS, 2010
- Life Expectancy After HIV Diagnosis Based on National HIV Surveillance Data From 25 States, United StatesJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- Long term management of people with HIV.2009
- Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studiesThe Lancet, 2008
- Survival of Persons with and without HIV Infection in Denmark, 1995–2005Annals of Internal Medicine, 2007
- HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysisThe Lancet, 2006
- The Changing Incidence of AIDS Events in Patients Receiving Highly Active Antiretroviral TherapyArchives of internal medicine (1960), 2005